Safety and efficacy of prophylaxis and on-demand treatment with BAY 94-9027: results of a phase 2/3 multicentre, partially randomized, open-label trial

被引：0
|
作者：
Reding, Mark [1 ]
Powell, Jerry [2 ]
Santagostino, Elena [3 ]
Ng, Heng Joo [4 ]
Lederman, Mel [5 ]
Wang, Maria [5 ]
Walsch, Rene [6 ]
Sax, Mirjam [7 ]
Michaels, Lisa A. [5 ]
机构：
[1] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA
[2] Univ Calif Davis, Sacramento, CA 95817 USA
[3] Maggiore Hosp Policlin, IRCCS Ca Granda Fdn, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy
[4] Singapore Gen Hosp, Dept Haematol, Singapore, Singapore
[5] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[6] Bayer Vital GmbH, Leverkusen, Germany
[7] Bayer Pharma AG, Berlin, Germany
来源：
HAEMOPHILIA | 2014年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [1] PROTECT VIII Kids trial results: BAY 94-9027 safety and efficacy in previously treated children with severe hemophilia A
    Santagostino, Elena
    Saxena, Kapil
    Kenet, Gili
    Fischer, Kathelijn
    Biss, Tina
    Radke, Susan
    Michaels, Lisa A.
    HAEMOPHILIA, 2016, 22 : 41 - 41
  • [2] Safety of long-term prophylaxis with BAY 94-9027: Interim results of >5 years of treatment in the PROTECT VIII extension trial
    Reding, Mark T.
    Ng, Hen Joo
    Tseneklidou-Stoefer, Despina
    Linardi, Camila
    Lalezari, Shadan
    HAEMOPHILIA, 2018, 24 : 17 - 18
  • [3] SAFETY AND EFFICACY OF BAY 94-9027 PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA A: INTERIM RESULTS OF A POST-MARKETING INTERVENTIONAL STUDY
    Holme, P. A.
    Poulsen, L. H.
    Enriquez, M. Maas
    Tueckmantel, C.
    Alvarez Roman, M. T.
    De Cristofaro, R.
    HAEMOPHILIA, 2021, 27 : 125 - 126
  • [4] Site specific PEGylated factor VIII BAY 94-9027: update on the results of the completed Phase 1 and Phase 2/3 studies
    Powell, Jerry
    Fischer, Kathelijn
    Kerlin, Bryce A.
    Shah, Anita
    Michaels, Lisa A.
    HAEMOPHILIA, 2014, 20 : 187 - 187
  • [5] Multicentre, randomized, open-label study of on-demand treatment with two prophylaxis regimens of recombinant coagulation factor IX in haemophilia B subjects
    Valentino, L. A.
    Rusen, L.
    Elezovic, I.
    Smith, L. M.
    Korth-Bradley, J. M.
    Rendo, P.
    HAEMOPHILIA, 2014, 20 (03) : 398 - 406
  • [6] Garadacimab for hereditary angioedema prophylaxis: Efficacy and safety from a Phase 2 open-label extension trial
    Craig, T. J.
    Reshef, A.
    Lumry, W. R.
    Saguer, I. Martinez
    Jacobs, J. S.
    Yang, W. H.
    Aygoren-Pursun, E.
    Keith, P. K.
    Busse, P.
    Magerl, M.
    Feuersenger, H.
    Bica, M. A.
    Glassman, F.
    Pragst, I.
    Levy, D. S.
    ALLERGOLOGIE, 2023, 46 (08) : 560 - 561
  • [7] Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study
    Reding, Mark T.
    Pabinger, Ingrid
    Holme, Pal Andre
    Poulsen, Lone
    Negrier, Claude
    Chalasani, Pavani
    Enriquez, Monika Maas
    Wang, Maria
    Meijer, Karina
    Mancuso, Maria Elisa
    Lalezari, Shadan
    HAEMOPHILIA, 2021, 27 (03) : E347 - E356
  • [8] An open-label phase I study to evaluate the pharmacokinetics and safety profile of Bay 94-9027, a PEGylated B-domain-deleted recombinant factor VIII, in previously treated patients with severe hemophilia A
    Coyle, T.
    Reding, M.
    Lin, J.
    Michaels, L.
    Shah, A.
    Powell, J.
    HAEMOPHILIA, 2012, 18 : 22 - 22
  • [9] Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
    Young, Guy
    Srivastava, Alok
    Kavakli, Kaan
    Ross, Cecil
    Sathar, Jameela
    You, Chur-Woo
    Tran, Huyen
    Sun, Jing
    Wu, Runhui
    Poloskey, Stacey
    Qiu, Zhiying
    Kichou, Salim
    Andersson, Shauna
    Mei, Baisong
    Rangarajan, Savita
    LANCET, 2023, 401 (10386): : 1427 - 1437
  • [10] Efficacy, safety and population pharmacokinetics of sapropterin in PKU patients < 4 years: results from the SPARK open-label, multicentre, randomized phase IIIb trial
    Muntau, Ania C.
    Burlina, Alberto
    Eyskens, Francois
    Freisinger, Peter
    De Laet, Corinne
    Leuzzi, Vincenzo
    Rutsch, Frank
    Sivri, H. Serap
    Vijay, Suresh
    Bal, Milva Orquidea
    Gramer, Gwendolyn
    Pazdirkova, Renata
    Cleary, Maureen
    Lotz-Havla, Amelie S.
    Munafo, Alain
    Mould, Diane R.
    Moreau-Stucker, Flavie
    Rogoff, Daniela
    ORPHANET JOURNAL OF RARE DISEASES, 2017, 12
12345